Neurotech extends licence to include all neurological disorders by Martin Lane March 3, 2021March 3, 2021 ASX-listed Neurotech International has announced the expansion of its exclusive licence with Dolce Cann Global to […]
Neurotech International completes in-vitro studies of its proprietary cannabis leads, clinical trials to follow by Martin Lane December 22, 2020December 22, 2020
Neurotech International’s new chairman to focus on cannabis treatments for cognitive disorders by Emma Castle November 2, 2020November 2, 2020
